Vertex Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Vertex Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Vertex Pharmaceuticals Inc Strategy Report
- Understand Vertex Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreVertex Pharmaceuticals Inc (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on cystic fibrosis, sickle cell diseases, beta thalassemia, type-1 diabetes and pain. It uses state-of-the-art technology platforms to discover new disease targets, compounds, delivery mechanisms, and treatment modalities. Vertex has R&D centers and commercial offices in North America, South America, Europe, and Australia. The company offers its products in the US, Europe, Australia, and Canada. Vertex is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
50 Northern Avenue, Boston, Massachusetts, 02210
Website
www.vrtx.com
Telephone
1 617 3416100
No of Employees
5,400
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VRTX (NASD)
Revenue (2022)
$9.9B
10.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
9%
(2022 vs 2021)
Market Cap*
$101.6B
Net Profit Margin (2022)
XYZ
-1.4%
(2022 vs 2021)
* As of and is in US$
Vertex Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Trikafta - Cystic Fibrosis |
| Symdeko/Symkevi - Cystic Fibrosis |
| Orkambi - Cystic Fibrosis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company signed an agreement to acquire Alpine Immune Sciences, Inc. for US$4.9 billion. |
| 2024 | Others | In April, the company announced the advancement of inaxaplin (VX-147) into the Phase III segment of the global Phase II/III pivotal trial for APOL1-mediated kidney disease. |
| 2024 | Regulatory Approval | In March, the company received approval from the U.S. Food and Drug Administration for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease in patients with a subset of PKD1 genetic variants. |
Competitor Comparison
| Key Parameters | Vertex Pharmaceuticals Inc | AbbVie Inc | Novartis AG | Arcturus Therapeutics Holdings Inc | Krystal Biotech Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | Boston | North Chicago | Basel | San Diego | Pittsburgh |
| State/Province | Massachusetts | Illinois | - | California | Pennsylvania |
| No. of Employees | 5,400 | 50,000 | 76,057 | 180 | 229 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jeffrey M. Leiden, M.D., Ph.D. | Chairman | Executive Board | 2020 | 67 |
| Reshma Kewalramani, M.D. | Chief Executive Officer; Director; President | Executive Board | 2020 | 50 |
| Charles F. Wagner | Chief Financial Officer; Executive Vice President | Senior Management | 2019 | 54 |
| Stuart A. Arbuckle | Chief Operating Officer; Executive Vice President | Senior Management | 2021 | 57 |
| Kristen C. Ambrose | Chief Accounting Officer; Senior Vice President | Senior Management | 2021 | 46 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward